Europe Calls On Pfizer/BioNtech For 200M More COVID-19 Vaccine Doses

The European Commission has announced an agreement with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for 200 million more doses of its COVID-19 vaccine in addition to the 300 million doses committed to the EU through this year.
The EC has the option to request a supply of an additional 100 million doses.
Additional 200 million doses are to be delivered in 2021, with around 75 million to be supplied in the second quarter.
Earlier this month, the U.K. launched a study to test whether alternating the AstraZeneca plc AZN and Pfizer/BioNTech COVID-19 vaccines in a two-shot schedule is safe and effective in fighting the infection.
Both the companies also withdrew their application for the emergency-use nod of its COVID-19 vaccine in India after failing to meet the drug regulator’s demand for local safety and immunogenicity trial.
BioNTech started production at a new COVID-19 vaccine factory in Marburg, Germany, with an annual production capacity of up to 750 million doses of COVID-19 vaccine, once fully operational.
Price Action: PFE is up 0.03% at $34.7, and BNTX is up 0.5% at $115 in premarket hours on the last check Wednesday.